Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Otsuka

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Otsuka's 2012 sales performance.

Otsuka

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report

4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD).

Digital divergence

Digital divergence Failed relationships. What we’ve seen recently – for example when Otsuka and Proteus ended their collaboration – is a number of pharma companies looking at digital partners, seeing value in getting together,

Teva’s weak pipeline hit by Tourette’s drug trial failure

Teva’s weak pipeline hit by Tourette’s drug trial failure 110 and Otsuka’s well-established antipsychotic drug Abilify (aripiprazole), which is in a trial with data due next year.

Merck strengthens KRAS stake with Taiho and Astex partnership

Merck strengthens KRAS stake with Taiho and Astex partnership Partner companies could gain $2.5bn in milestone payments. Merck &Co/MSD has announced a partnership with Otsuka's Taiho unit and Cambridge, UK-based biotech Astex Pharmaceuticals for the development ... Otsuka’s Taiho has retained co-commercialisation

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Low-dose LSD looks safe for Alzheimer’s patients, but will it work? Other treatments targeting serotonin pathways in Alzheimer’s haven’t proved to be successful – such as Lundbeck and Otsuka’s 5-HT.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...